Compare Eni SpA (E) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs State Street SPDR S&P Biotech ETF — how do they compare? Eni SpA trades at $56 (market cap $79.81B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: Eni SpA is far larger — about 7.9× State Street SPDR S&P Biotech ETF's market cap, and Eni SpA pays a 4.39% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| E | XBI | |
|---|---|---|
Market Cap | $79.81B | $10.11B |
Volume | 365,912 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $57.61 | $169.55 |
52-Week Low | $34.03 | $104.99 |
Typical Hold Time | 53 Days | 37 Days |
Enterprise Value | $104.34B | — |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.
The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
